There are currently a number of ongoing clinical trials for acute myeloid leukemia (AML) that are targeting nuclear exporters. In this video, recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Ramiro Garzon, MD, from Ohio State University, Columbus, OH, discusses the promise of these novel agents.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates